TRIPS-plus and access to medicines in China

Area of Science:

• Health Policy
• Intellectual Property Law
• International Trade Law

Background:

• Trade-related aspects of intellectual property rights (TRIPS)-plus provisions often exceed minimum requirements, potentially hindering access to medicines.
• Developed nations are increasingly pressuring developing countries to adopt stricter intellectual property (IP) protections beyond the TRIPS Agreement.
• Limited access to essential medicines poses significant public health challenges in developing economies.

Purpose of the Study:

• To analyze the impact of TRIPS-plus provisions on medicine accessibility and availability in China.
• To investigate the specific TRIPS-plus arrangements within China's intellectual property legal framework.
• To propose strategic recommendations for China's negotiations to safeguard public health interests regarding IP laws.

Main Methods:

• Policy analysis of Chinese intellectual property laws and regulations.
• Review of international agreements and trade-related intellectual property rights (TRIPS) standards.
• Comparative analysis of TRIPS-plus provisions and their implications for medicine access.

Main Results:

• TRIPS-plus provisions in China's IP laws may create barriers to accessing affordable medicines.
• Existing Chinese IP regulations contain elements that align with TRIPS-plus standards, potentially impacting pharmaceutical availability.
• The study identifies specific areas within Chinese IP law that warrant careful consideration during international negotiations.

Conclusions:

• China faces pressure to implement TRIPS-plus provisions, which could compromise medicine access and public health.
• Strategic negotiation is crucial for China to balance IP protection with the imperative of ensuring affordable access to medicines.
• Recommendations are provided to guide China's approach in resisting overly stringent IP regulations that could harm health outcomes.